Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097369 · ClinicalTrials.gov registry record
Elitek (Rasburicase) Immuno-Monitoring Study
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01097369 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 1 participants.
The verdict
NCT01097369 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097369
The ClinicalTrials.gov registry entry for NCT01097369 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01097369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01097369 about?
NCT01097369 is a clinical study titled "Elitek (Rasburicase) Immuno-Monitoring Study". Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hyper...
What is the current status of trial NCT01097369?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2010-02. Estimated completion is 2010-02.
Who is sponsoring clinical trial NCT01097369?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.